From: Nanomedicine review: clinical developments in liposomal applications
References | Disease | LF | Toxicitya Grade 3–5 (%) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
N | A | T | L | Na | D | V | P | Ast | |||
Wang and Zhang (2014) | NSCLC | L-PTX + carboplatin |  | 13 |  | 57 |  |  |  |  |  |
Lu et al. (2015) | NSCLC | L-PTX + gemcitabine + carboplatin | 14 | 4 | 2 |  | 2 | 4 | 2 |  |  |
Ahn et al. (2014) | NSCLC | Genexol-PM + gemcitabine | 16 |  |  |  |  | 3 |  |  | 7 |
Ignatiadis et al. (2016) | BC | EndoTAG-1 + paclitaxel + fluorouracil + epirubicin + cyclophosphamide | 7 |  |  |  |  |  |  |  |  |
Awada et al. (2014) | TNBC | EndoTAG-1 + paclitaxel | 22 | 2 |  | 7 |  |  | 2 | 2 | 6 |
EndoTAG-1 | 5 | Â | Â | 2 | Â | 2 | Â | 4 | 5 | ||
Lu et al. (2016) | AGC | L-PTX + capecitabine |  | 2.9 |  | 17.6 |  |  |  |  |  |
Xu et al. (2013) | MGC | Lipusu® |  | 3 |  | 7 | 3 |  | 3 |  |  |
Haas et al. (2012) | APC | EndoTAG-1 + gemcitabine | 12 |  | 8 | 10 |  |  | 2 |  |  |
16 | 4 | 16 | 12 | Â | Â | Â | 6 | Â | |||
22 | 8 | 14 | 10 | 6 | Â | 4 | 8 | Â | |||
Graziani et al. (2017)b | EOC | PTX–LCN |  |  |  |  |  |  |  |  |  |
Strieth et al. (2013)c | HNC | EndoTAG-1 | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Slingerland et al. (2017)d | AC | LEP-ETU | 17 | Â | Â | 3 | Â | Â | Â | Â | Â |